



Report of the Fourth Meeting of the Pandemic Influenza Preparedness (PIP) Framework 2016 Review Group

ORGANIZATION AND PROCESS OF THE MEETING

1. The fourth meeting of the PIP Framework Review Group was held at WHO Headquarters from 9 through 11 May. The meeting included in its agenda:
 - Interviews with key informants;
 - Discussion of strengths, weaknesses, opportunities and threats of different elements of the PIP Framework;
 - Discussion of the outline of the final report.
2. Seven of the eight members of the Review Group, attended the meeting (names and affiliations of the members are listed in Annex 1). Dr Viroj Tangcharoensathien was absent, and sent apologies.

OPENING OF THE MEETING

3. Due to the delayed arrival of the Chair, Dr Christine Mwelwa Kaseba-Sata, Dr Theresa Tam chaired the first day of the meeting.
4. Dr Tam welcomed members to the meeting and led a discussion of the agenda.

KEY INFORMANT INTERVIEWS

5. The WHO Secretariat provided an overview of the progress of the Global Action Plan for Influenza Vaccines (GAP), linkages between GAP and the PIP Framework, and how the work of GAP could be continued after GAP ends.
6. The WHO Secretariat further updated the Review Group on the Advisory Group's progress in considering the best process for the handling of genetic sequence data.
7. During the meeting, the Review Group held several interviews with key informants.
8. In addition, the Review Group analysed interviews conducted prior to this meeting.

DISCUSSION OF STRENGTHS, WEAKNESSES, OPPORTUNITIES AND THREATS

9. The Review Group revised a table of strengths, weaknesses, opportunities and threats (SWOT) developed at their last meeting. Topics discussed included, among others:
- The centrality of the reciprocity of virus sharing and benefit sharing to the implementation of the PIP Framework;
 - The promotion of the PIP Framework and progress reports of benefit sharing;
 - The timeliness and completeness of virus sharing within GISRS, and barriers to sharing;
 - The geographical coverage of the GISRS network;
 - The timeliness and robustness of risk assessment;
 - The PIP Framework Advisory Group process for considering the handling of GSD;
 - The need to increase the level of understanding of the PIP Framework among Member States, companies, civil society, and other stakeholders;
 - Opportunities and challenges in concluding additional SMTA2 agreements with recipients of PIP biological materials;
 - The relationship between seasonal vaccine capacity and pandemic vaccine capacity, and how these capacities could be strengthened;
 - The relationship between the PIP Framework and antiviral stockpiles, and the role of such stockpiles in increasing pandemic preparedness;
 - The collection of partnership contribution payments under the PIP Framework;
 - The calculation of GISRS running costs and of the distribution of PC contributions among companies;
 - How the recipients of partnership contribution funds are prioritized and metrics for monitoring progress;
 - The duration of membership and reporting requirements of the PIP Framework Advisory Group;
 - The PIP Framework Advisory Group's communication with Member States, industry, civil society and other stakeholders;
 - The PIP Framework as a potential model for other public-private partnerships and for the handling of non-influenza pathogens;
 - Synergies between and challenges faced in the interaction between PIP and other instruments and initiatives, such as the International Health Regulations (2005), Global Action Plan for Influenza Vaccines, and the Nagoya Protocol;
 - The PIP Framework as a potential specialized instrument under the Nagoya Protocol;
 - The impact of the closing of the GAP programme in 2016.

DISCUSSION OF THE FINAL REPORT AND NEXT STEPS

10. The Review Group discussed and agreed on the outline of their final report.
11. The Review Group reviewed and approved the meeting report.
12. The Review Group considered next steps, including the schedule of interviews with additional key informants.
13. The Chair thanked the members and closed the meeting.

ANNEX 1

MEMBERS OF THE REVIEW COMMITTEE

Review Group Members	Affiliation
Professor William Kwabena Ampofo	Head of Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
Dr Christine Mwelwa Kaseba-Sata (Chair)	Former WHO Goodwill Ambassador against Gender-based Violence, Zambia
Dr Frances McGrath	Chief Advisor, Clinical Leadership, Protection and Regulation, Ministry of Health, New Zealand
Dr Talat Mokhtari-Azad,	Director, Iranian National Influenza Center
Ms Johanne Newstead	Head of Food Policy, Public Health Directorate, Department of Health, United Kingdom
Dr Theresa Tam	Deputy Chief Public Health Officer of the Public Health Agency of Canada
Dr Viroj Tangcharoensathien	Senior Adviser, International Health Policy Program, Ministry of Public Health, Thailand
Prof Dr Makarim Wibisono	Chairman, Governing Board of Indonesia Council of World Affairs